YK-11

Research records

Historical source snapshot. Not freshly verified, not a recommendation. Study findings, community accounts and app defaults are not interchangeable.

Publication suitability · 2026-10-15: Historical reference only; not a clinical verification. Clinical, regulatory, efficacy, safety and dose claims are not independently established by this review.

YK-11

An experimental selective androgen receptor modulator with myostatin-inhibiting properties and documented neurological risks.

Evidence category: Preclinical. This describes the source category, not approval or certainty.

Regulatory statement in source: Not separately recorded; do not infer approval from the evidence category.

YK-11 is a synthetic steroidal selective androgen receptor modulator first studied in 2011 by Japanese researcher Yuihi Kanno. It functions as a partial AR agonist and uniquely suppresses myostatin by upregulating follistatin. Recent research indicates YK-11 may promote oxidative stress and mitochondrial dysfunction, with potential neurological risks affecting memory consolidation.

Benefits reported in the imported source

• Myostatin inhibition via follistatin upregulation in vitro

Risks and limits

• No validated clinical studies to date
• Promotes oxidative stress and mitochondrial dysfunction
• Impairs memory consolidation at anabolic doses
• Safety, pharmacokinetics, and long-term effects poorly characterized

Source bottom line: Experimental compound with preclinical myostatin-inhibiting promise but documented neurological and mitochondrial risks.

Uncertainty: Reference information only. Not medical advice.

Study protocols — reports, not instructions

No study protocol recorded in this snapshot. This does not establish that no study exists.

Community and practice descriptions

Accounts of a practice are not evidence of safety or effectiveness. Words such as “standard”, “safe” or “recommended” describe the source account, not verified consensus or this wiki’s advice. Commercial and self-published citations are retained for traceability, not vendor endorsement or independent clinical corroboration.

No community description recorded. This entry has no final B-82 outcome record; it is not a researched-empty finding.

Pharmacokinetic context

No half-life recorded in this source snapshot. No value has been inferred.

Source references

• YK11 Hippocampal Function - PubMed Central
• YK-11 and Myostatin Inhibition - ChemicalBook